Wall Street Journal
As High-Cost Treatments Vie, Express Scripts Opts to Use AbbVie’s Over Gilead’s
Express Scripts said the decision will go into effect Jan. 1, and apply to 25 million beneficiaries whose employers contract with the company directly The St. Louis-based company will also encourage all of itscustomers, including those it serves through large health insurers, to make the change, Chief Medical Officer Steve Miller said in an interview. “Many of them will adopt these recommendations,” he said.
The Hottest Biotech IPO of the Year Arrives This Week
December 15, 2014 6:42 AM Adam on Biotech Stocks Follow on Tumblr
Bellicum Pharmaceuticals and Juno Therapeutics are expected to raise more than $300 million combined through their respective initial public offering. Both companies are developing CAR-T therapies, which use re-engineered immune cells to seek out and kill blood cancer cells. Early clinical trials involving this new form of cancer immunotherapy have delivered amazing results and generated huge investor inteest.Other CAR-T companies include Kite Therapeutics and a joint venture between Celgene and Bluebird B
BLUE has 220 million in cash, no need for secondary, but nice try shorts. Just cover and move on
You're embarrassing yourselves
Conference Call " If We Continue Good Data, Good Things Will Come"
GILD Abbie etc...
Alibaba Expands In India, Rural China And Promotes Alipay
BenzingaBy Kevin Riley 4 hours ago